CTLA4 and melanoma: In another preclinical study, the small molecule TRT agent 177Lu-LLP2A, targeting very late antigen-4 (VLA-4), when combined with anti-CTLA-4, anti-PD-1, or anti-PD-L1 resulted in improved survival of mice bearing B16F10 melanoma tumors.